Pharma is rapidly adapting its approach to trials in the face of the pandemic and there is great opportunity for far reaching improvements once this is all over
Individualised medicine has so far failed to live up to the hype but innovations in the field are on the cusp of disrupting the way pharma and healthcare develop and provide treatments.